Did you have a look at the date & BRD's shareprice when this was published? If there was something to it, one would have expected the sp to do just a little bit better . . . .
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling